An observational study in Tuberculosis (TB) and End-Stage Kidney Disease, sponsored by Mahidol University. Active, not recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Mahidol University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Tuberculosis with a site in Thailand — 5 open to participants now, 8 under way, 1 of them phase 3. Tuberculosis · Thailand.
Among the 36 studies in Tuberculosis with a site in Thailand, this one is one of 4 that started in 2024, is one of 6 observational ones, and was the 34th registered.
1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.
Browse Tuberculosis studies →5 of the 36 studies in Tuberculosis with a site in Thailand are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Thailand, Botswana, Haiti and 3 more countries
Ages up to 13
Mahidol University · Sites in Thailand
Ages 18–80
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Thailand, Brazil, India and 9 more countries
Ages 15+
University of Oxford · Sites in Thailand
Ages 18+ · Healthy volunteers
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in Thailand, Argentina, Australia and 13 more countries
Ages 13+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 6 · Phase 4 5
First in 2005; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is below the median of 252 across 318 observational studies indexed under Tuberculosis.
Median enrollment 130 across the 30 interventional studies, 147 across the 6 observational. Of the 25 that completed or were terminated, 11 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 36 have an industry lead sponsor. The 10 most frequent:
Mahidol University is the lead sponsor of 750 studies on the registry; 123 are open to participants now.
Mahidol University has 4 studies filed under Tuberculosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Tuberculosis with a site in Thailand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06700876Mahidol UniversityEvaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Tuberculosis with a site in Thailand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study among approximately 160 end-stage renal disease patients on renal replacement therapy and post-living donor or deceased donor kidney transplant recipients. Investigators aim to assess the proportion of positive IGRA associated with symptom development, sputum Xpert MTB/RIF assay, and chest radiograph to define latent TB infection and subclinical TB among ESKD and renal transplant patients.
Patients with chronic kidney disease and end-stage kidney disease (ESKD) are at risk of developing tuberculosis and are often delayed in diagnosis. Herein, investigators aim to assess the proportion of positive IGRA associated with symptom development, sputum Xpert MTB/RIF assay, and chest radiograph to define latent TB infection and subclinical TB among ESKD and renal transplant patients.
End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation aged more than or equal 18 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
End-stage renal disease on renal replacement therapy (hemodialysis or peritoneal dialysis) or status-post-living donor or deceased donor kidney transplantation aged more than or equal 18 years
1.The number of participants with positive IGRAs among end-stage kidney disease and kidney transplant patients
The number of participants with positive IGRAs among end-stage kidney disease patients and kidney transplant patients
Time frame: A prospective cohort study with following up period 2 years
2. The number of participants with latent TB and active TB among end-stage kidney disease and kidney transplant patients during the 2-year follow-up defined by:
1. Latent TB: a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens (positive IGRA) with no evidence of clinically manifest active TB 2. Active TB: a disease in someone infected with Mycobacterium tuberculosis. It is characterized by signs or symptoms of active disease, or both, and is distinct from latent TB infection, which occurs without signs or symptoms of active disease
Time frame: A prospective cohort study with following up period 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 123 non-industry observational studies under Tuberculosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 28 months is below that.
Counting every sponsor, half of 135 studies reached it within 36 months; a quarter within 21 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.